Bortezomib

Proteasome inhibitor preventing premature CFTR breakdown

Phase of research

FDA-/EMA-approved for Other Purpose

How it helps

Restore CFTR Function

General information

Bortezomib is an anti-cancer medication used to treat multiple myeloma and mantle cell lymphoma. It was approved in the USA in 2003 for medical use and is sold under the name Velcade®. In relation to cystic fibrosis, our AIM tool found the data that bortezomib can help rescue the misfolded F508del-CFTR by inhibiting its degradation.

Bortezomib on PubChem
Bortezomib on DrugBank
Bortezomib on Wikipedia

Synonyms

PS341

Marketed as

Velcade - prescribing information

Dietary sources

N/A

Structure image not available

C₁₉H₂₅BN₄O₄

Drug-Mutation Relation

results for D1152H / F508del

See all data on Bortezomib

Treats

Mutation	Link	Tested on	Impact factor	Notes
F508del	Rescue of Murine F508del CFTR Activity in Native Intestine by Low Temperature and Proteasome Inhibitors	murine cell cultures	3.73
F508del	High-content Functional Screen to Identify Proteins that Correct F508del-CFTR Function*S⃞	human cell cultures	7.52

Does not treat

Mutation	Link	Tested on	Impact factor	Notes